HTR2C
ENSG00000147246
Target class
GPCR
Chromosome
X
Approved drugs
30
Clinical candidates (approved and in development)
34
- Approved drugs
- 30
- Clinical candidates (approved and in development)
- 34
- Chemical probe available
- Yes
- Target name
- HTR2C
- Gene name
- 5-hydroxytryptamine receptor 2C
- Gene symbol
- HTR2C
- Previous gene symbols
- HTR1C
- Protein name
- 5-hydroxytryptamine receptor 2C (5-HT-2C) (5-HT2C) (5-HTR2C) (5-hydroxytryptamine receptor 1C) (5-HT-1C) (5-HT1C) (Serotonin receptor 2C)
- 5-HT2C
- 5HTR2C
- Gene biotype
- Protein coding
- Gene family
- 5-hydroxytryptamine receptors, G protein-coupled|MicroRNA protein coding host genes|Small nucleolar RNA protein coding host genes
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 9
- Highest tissue expression
- 31.82
- Tissue specificity (Gini)
- 0.917
- Tissue specificity (tau)
- 0.974
- KEGG gene identifiers
- hsa:3358
- Protein interaction confidence
- 0.861955
- Protein interaction partners
- 22
- R-HSA-390666
- R-HSA-416476
- End position
- 114910061
- Start position
- 114584078
- Chromosome
- X
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- PubMed 12970106
- PubMed 18703043
- PubMed 19057895
- PubMed 7895773
- Tissue specificity (tau)
- 0.973845
- Expression inequality (Gini)
- 0.916675
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)
- 31.82
- Brain - Caudate (basal ganglia)
- 13.82
- Brain - Hypothalamus
- 13.27
- Brain - Putamen (basal ganglia)
- 6.38
- Brain - Amygdala
- 2.61
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)31.82
- Brain - Caudate (basal ganglia)13.82
- Brain - Hypothalamus13.27
- Brain - Putamen (basal ganglia)6.38
- Brain - Amygdala2.61
- Brain - Anterior cingulate cortex (BA24)1.71
- Brain - Frontal Cortex (BA9)1.37
- Brain - Hippocampus1.32
- Brain - Substantia nigra1.29
- Brain - Cortex0.73
- Brain - Spinal cord (cervical c-1)0.6
- Vagina0.32
- Brain - Cerebellar Hemisphere0.11
- Cervix - Ectocervix0.11
- Cervix - Endocervix0.09
- Testis0.09
- Brain - Cerebellum0.08
- Nerve - Tibial0.07
- Bladder0.06
- Prostate0.04
- Pituitary0.02
- Skin - Sun Exposed (Lower leg)0.01
- Minor Salivary Gland0.01
- Esophagus - Gastroesophageal Junction0
- Kidney - Cortex0
And 29 more, listed on the interactive page.
- GO:0006874
- GO:0007208
- GO:0007268
- GO:0007631
- GO:0010513
- GO:0051209
- GO:0070374
- GO:0098664
- GO:0005886
- GO:0098666
- GO:0001587
- GO:0004993
- GO:0005515
- GO:0042802
- GO:0051378
- GO:0071886
increased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased convulsions
Biological samples
- nervous system
PubMed 28216264decreased locomotor activity
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased locomotor activity
Biological samples
- nervous system
PubMed 28216264increased anxiety
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased anxiety
Biological samples
- nervous system
PubMed 28216264increased memory
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased memory
Biological samples
- nervous system
PubMed 28216264abnormal mouth movements
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: abnormal mouth movements
Biological samples
- nervous system
PubMed 28216264penile erection
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: penile erection
Biological samples
- nervous system
PubMed 28216264decreased convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased convulsions
Biological samples
- nervous system
PubMed 28216264decreased eating
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased eating
Biological samples
- nervous system
PubMed 28216264Increased, Kidney Failure
Effects
- Activation/Increase/Upregulation
Studies
- cell-based
Evidence sourcedrug abuse/dependence
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: drug abuse/dependence
Biological samples
- nervous system
PubMed 28216264decreased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased memory
Biological samples
- nervous system
PubMed 28216264decreased anxiety
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased anxiety
Biological samples
- nervous system
PubMed 28216264
Related records
Trials (1,487)
- "Extended" (Alternate Day) Antipsychotic Dosing
- "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
- 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
- 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
- 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
- 15 mg Mirtazapine Orally Disintegrating Tablets, Fasting
- 15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting
- 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years
- 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
- 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
- 3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects
- 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
- 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
- 5HT2CR Balance in Brain Connectivity in Cocaine Dependence
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
- 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)
- A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
- A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome
Drugs (50)
- Agomelatine Serotonin 2c (5-HT2c) receptor antagonist
- Amisulpride Serotonin (5-HT) receptor antagonist
- Carphenazine Serotonin 2c (5-HT2c) receptor antagonist
- Carphenazine maleate Serotonin 2c (5-HT2c) receptor antagonist
- Chlorprothixene Serotonin 2c (5-HT2c) receptor antagonist
- Clothiapine Serotonin 2 (5-HT2) receptor antagonist
- Cyclobenzaprine Serotonin 2c (5-HT2c) receptor antagonist
- Cyclobenzaprine hydrochloride Serotonin 2c (5-HT2c) receptor antagonist
- Dexfenfluramine Serotonin (5-HT) receptor agonist
- Dexfenfluramine hydrochloride Serotonin (5-HT) receptor agonist
- Esmirtazapine Serotonin 2c (5-HT2c) receptor antagonist
- Esmirtazapine maleate Serotonin 2c (5-HT2c) receptor antagonist
- Fenfluramine Serotonin 2c (5-HT2c) receptor agonist
- Fenfluramine hydrochloride Serotonin 2c (5-HT2c) receptor agonist
- Lorcaserin Serotonin 2c (5-HT2c) receptor agonist
- Lorcaserin hydrochloride Serotonin 2c (5-HT2c) receptor agonist
- Loxapine Serotonin 2c (5-HT2c) receptor antagonist
- Loxapine hydrochloride Serotonin 2c (5-HT2c) receptor antagonist
- Loxapine succinate Serotonin 2c (5-HT2c) receptor antagonist
- Methixene Serotonin 2c (5-HT2c) receptor antagonist